Furthermore, studies have illustrated the interplay between FGFRs and EGFRs in other cancer types, and a combination treatment with EGFR inhibitor, erlotinib, increased the sensitivity to PD173074 inhibition in CCA cell lines. The gene discussed is EGFR; the disease is cancer.